CareDx released validation data for AlloHeme, its allogeneic hematopoietic cell transplant surveillance assay, showing 85% sensitivity, 92% specificity and a median 41‑day lead time in detecting clinical relapse. The results come from the observational ACROBAT study across multiple US sites and compared favorably with current bone‑marrow biopsy–based standards. Investigators emphasized high negative predictive value and the potential for earlier intervention given the assay’s lead time over clinical relapse. CareDx said it will publish the ACROBAT data and lay commercial groundwork ahead of a planned market launch next year. If implemented, AlloHeme could change post‑transplant monitoring by reducing reliance on invasive testing and enabling earlier therapeutic decisions based on cfDNA signals.